MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

The IPO market for med-tech companies continues to set new records. With one IPO closed the last week of June, two slated for ...

Inmune Bio Inc. claimed a phase II win with TNF inhibitor Xpro (pegipanermin) in early Alzheimer’s disease (AD), though the ...

Monoclonal antibodies show strong therapeutic potential against neurodegenerative diseases, but a major challenge is ensuring ...

Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 ...

Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane ...

The top 10 biopharma stock gainers and losers for the week.

Solid phase III efficacy results for Moderna Inc.’s seasonal influenza vaccine, mRNA-1010, may lead the company to resubmit a ...

Shemyakin Institute of Bioorganic Chemistry has synthesized perylenylethynylphenol derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of SARS-CoV-2 ...

Many cancers involve upregulation of Aurora kinase B, which helps deregulate normal cell cycling to drive tumor proliferation. The kinase should therefore be a good therapeutic target, yet no ...

The efficacy of camptothecin-based topoisomerase I (Topo1) inhibitors, which are widely used as anticancer therapies, is often limited by resistance mechanisms, primarily involving mutations in the ...

Sunshine Lake Pharma Co. Ltd. has disclosed Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.